Education
About Us
Working with TipRanks
Follow Us
Treace Medical Concepts (TMCI)
NASDAQ:TMCI
Earnings Data
Report Date
May 13, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.31Last Year’s EPS
-0.25Same Quarter Last Year
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a mixed picture: the company demonstrated meaningful operational progress — expanding its product portfolio, accelerating surgeon adoption, materially reducing cash burn and improving full-year adjusted EBITDA vs prior year — and secured liquidity. However, these positives are offset by near-term revenue pressure driven by a mix shift toward lower-priced products, market softness in elective foot and ankle procedures, a sizable Q4 GAAP net loss increase, and guidance that implies flat-to-declining revenue for 2026 with an expectation of an adjusted EBITDA loss. Management expects improvements later in 2026 (stronger Q3/Q4) as new higher-ASP products launch and adoption deepens, but the current outlook and recent quarterly results temper the outlook.Company Guidance
Expanded Product Portfolio and TAM Expansion
Launched 3 new bunion systems in 2025 (Nanoplasty, Percuplasty 3D MIS, SpeedMTP) plus ongoing Lapiplasty innovations (Micro-Lapiplasty, planned Lapiplasty Lightning and Speed TMT). Company estimates these new launches expand accessible market (TAM) materially and plans two additional 2026 launches that expand TAM by an estimated $300 million (SuperBite screws, Speed XM).
Surgeon Adoption and Training Momentum
Active surgeon base grew from ~1,300 in 2020 to over 3,300 in 2025. As of Q4 2025, over 25% of the surgeon base had incorporated one or more of the 3 new systems into practice just over two quarters into full launch; Q4 procedure volume growth increased above the mid-single-digit rates reported in Q3.
Improved Adjusted EBITDA and Reduced Cash Burn (Year-over-Year)
Full year 2025 adjusted EBITDA loss improved to $(3.9) million versus $(11.0) million in 2024, a 64% improvement. Full year 2025 cash used was $27.3 million versus $50.5 million in 2024, a 46% reduction in cash burn.
Strong Gross Margin and Quarterly Adjusted EBITDA
Fourth quarter 2025 gross margin remained stable at 80.6% (80.7% in Q4 2024). Q4 2025 adjusted EBITDA was $6.2 million (positive on a quarterly basis).
Balance Sheet Liquidity
Cash, cash equivalents and marketable securities totaled $48.4 million as of December 31, 2025, and the company secured a new credit facility providing an additional $115 million of available liquidity, subject to conditions.
2026 Operational Targets for Profitability and Cash Reduction
Management expects to reduce cash burn by approximately 50% in 2026 vs 2025 and provided a full-year adjusted EBITDA loss expectation of $(4) million to $(6) million for 2026 while continuing investments in product launches and targeted sales hires.
TMCI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TMCI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 27, 2026 | $2.10 | $1.86 | -11.43% |
Nov 06, 2025 | $6.23 | $4.46 | -28.41% |
Aug 07, 2025 | $5.68 | $6.13 | +7.92% |
May 08, 2025 | $7.54 | $6.82 | -9.55% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Treace Medical Concepts (TMCI) report earnings?
Treace Medical Concepts (TMCI) is schdueled to report earning on May 13, 2026, After Close (Confirmed).
What is Treace Medical Concepts (TMCI) earnings time?
Treace Medical Concepts (TMCI) earnings time is at May 13, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TMCI EPS forecast?
TMCI EPS forecast for the fiscal quarter 2026 (Q1) is -0.31.